Eli Lilly & Co (DE:LLY)

XETRA:LLY

LLY

Eli Lilly & Co

RESEARCH TOOLSreports

Eli Lilly & Co (LLY) Stock Forecast & Price Target

195 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

LLY Analyst Ratings

Strong Buy

17 Buy

2 Hold

1 Sell

Based on 20 analysts giving stock ratings to

Eli

Lilly & Co

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

LLY Stock 12 Month Forecast

Average Price Target

€1,069.06

▲(30.56% Upside)

Based on 20 Wall Street analysts offering 12 month price targets for Eli Lilly & Co in the last 3 months. The average price target is €1,069.06 with a high forecast of €1,286.08 and a low forecast of €728.78. The average price target represents a 30.56% change from the last price of €818.80.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"615":"€615","783":"€783","951":"€951","1119":"€1,119","1287":"€1,287"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1286.08431,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€1.29K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1069.0618696352,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€1.07K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":728.781109,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€728.78</span>\n  </div></div>","useHTML":true}}],"tickPositions":[615,783,951,1119,1287],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,823.5,859.0834084615385,894.6668169230769,930.2502253846154,965.8336338461538,1001.4170423076923,1037.0004507692308,1072.5838592307691,1108.1672676923076,1143.7506761538461,1179.3340846153847,1214.9174930769232,1250.5009015384617,{"y":1286.08431,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,823.5,842.3893745873231,861.2787491746461,880.1681237619692,899.0574983492924,917.9468729366154,936.8362475239385,955.7256221112616,974.6149966985847,993.5043712859077,1012.3937458732308,1031.2831204605538,1050.172495047877,{"y":1069.0618696352,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,823.5,816.2139314615384,808.9278629230769,801.6417943846154,794.3557258461539,787.0696573076923,779.7835887692307,772.4975202307693,765.2114516923077,757.9253831538462,750.6393146153846,743.3532460769231,736.0671775384616,{"y":728.781109,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":751.488,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 63,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":782.854,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 64,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":646.526,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 75,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":664.53,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 76,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":651.699,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 82,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":616.362,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 80,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":689.432,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 93,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":740.472,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 90,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":916.864,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 90,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":915.067,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 71,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":890.708,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 71,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":884.1,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 91,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":823.5,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 91,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€1,286

Average Price Target€1,069

Lowest Price Target€728.78

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Courtney Breen

Bernstein

€1,125.05

Buy

37.40%

Upside

Assigned

04/06/26

Analysts Are Bullish on Top Healthcare Stocks: Cigna (CI), Eli Lilly & Co (LLY)

Srikripa Devarakonda

Truist Financial

―

Buy

―

Reiterated

04/02/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Steve Scala

TD Cowen

€1,081.78

Buy

32.12%

Upside

Reiterated

04/02/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Chris Schott

J.P. Morgan

€1,125.05

Buy

37.40%

Upside

Reiterated

04/02/26

Analysts Offer Insights on Healthcare Companies: PDS Biotechnology (NASDAQ: PDSB), Eli Lilly & Co (NYSE: LLY) and Praxis Precision Medicines (NASDAQ: PRAX)

Seamus Fernandez

Guggenheim

€1,006.48

Buy

22.92%

Upside

Assigned

04/01/26

Eli Lilly price target lowered to $1,163 from $1,168 at GuggenheimEli Lilly price target lowered to $1,163 from $1,168 at Guggenheim

Mohit Bansal

Wells Fargo

€1,211.59→€1,107.74

Buy

35.29%

Upside

Reiterated

04/01/26

Eli Lilly & Co (LLY) Gets a Buy from Wells Fargo

Terence Flynn

Morgan Stanley

€1,116.39→€1,136.3

Buy

38.78%

Upside

Reiterated

04/01/26

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY) and Merit Medical Systems (NASDAQ: MMSI)

Asad Haider

Goldman Sachs

€990.91→€1,090.43

Buy

33.17%

Upside

Assigned

04/01/26

Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (NASDAQ: DFTX) and Eli Lilly & Co (NYSE: LLY)

Louise Chen

Scotiabank

€1,125.05

Buy

37.40%

Upside

Reiterated

04/01/26

Scotiabank Sticks to Their Buy Rating for Eli Lilly & Co (LLY)

Jason Gerberry

Bank of America Securities

―

Buy

―

Reiterated

03/31/26

Analysts' Top Healthcare Picks: Thermo Fisher (TMO), Eli Lilly & Co (LLY)

Geoff Meacham

Citi

€1,298.13

Buy

58.54%

Upside

Reiterated

03/31/26

Analysts Offer Insights on Healthcare Companies: Phreesia (NYSE: PHR), Palisade Bio (NASDAQ: PALI) and Eli Lilly & Co (NYSE: LLY)

Evan Seigerman

BMO Capital

€1,125.05

Buy

37.40%

Upside

Reiterated

03/31/26

Eli Lilly: Strategic Neuroscience Expansion and Diversified Growth Support Continued Buy Rating

David Risinger

Leerink Partners

€1,121.58

Buy

36.98%

Upside

Reiterated

03/30/26

Analysts' Top Healthcare Picks: Centene (CNC), Eli Lilly & Co (LLY)

Emily Field

Barclays

€1,168.32

Buy

42.69%

Upside

Reiterated

03/24/26

Barclays Sticks to Their Buy Rating for Eli Lilly & Co (LLY)

Trung Huynh

RBC Capital

€1,081.78

Buy

32.12%

Upside

Reiterated

03/19/26

Eli Lilly has "viable option' in type 2 diabetes, says RBC CapitalEli Lilly has "viable option' in type 2 diabetes, says RBC Capital

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Courtney Breen

Bernstein

€1,125.05

Buy

37.40%

Upside

Assigned

04/06/26

Analysts Are Bullish on Top Healthcare Stocks: Cigna (CI), Eli Lilly & Co (LLY)

Srikripa Devarakonda

Truist Financial

―

Buy

―

Reiterated

04/02/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Steve Scala

TD Cowen

€1,081.78

Buy

32.12%

Upside

Reiterated

04/02/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Chris Schott

J.P. Morgan

€1,125.05

Buy

37.40%

Upside

Reiterated

04/02/26

Analysts Offer Insights on Healthcare Companies: PDS Biotechnology (NASDAQ: PDSB), Eli Lilly & Co (NYSE: LLY) and Praxis Precision Medicines (NASDAQ: PRAX)

Seamus Fernandez

Guggenheim

€1,006.48

Buy

22.92%

Upside

Assigned

04/01/26

Eli Lilly price target lowered to $1,163 from $1,168 at GuggenheimEli Lilly price target lowered to $1,163 from $1,168 at Guggenheim

Mohit Bansal

Wells Fargo

€1,211.59→€1,107.74

Buy

35.29%

Upside

Reiterated

04/01/26

Eli Lilly & Co (LLY) Gets a Buy from Wells Fargo

Terence Flynn

Morgan Stanley

€1,116.39→€1,136.3

Buy

38.78%

Upside

Reiterated

04/01/26

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY) and Merit Medical Systems (NASDAQ: MMSI)

Asad Haider

Goldman Sachs

€990.91→€1,090.43

Buy

33.17%

Upside

Assigned

04/01/26

Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (NASDAQ: DFTX) and Eli Lilly & Co (NYSE: LLY)

Louise Chen

Scotiabank

€1,125.05

Buy

37.40%

Upside

Reiterated

04/01/26

Scotiabank Sticks to Their Buy Rating for Eli Lilly & Co (LLY)

Jason Gerberry

Bank of America Securities

―

Buy

―

Reiterated

03/31/26

Analysts' Top Healthcare Picks: Thermo Fisher (TMO), Eli Lilly & Co (LLY)

Geoff Meacham

Citi

€1,298.13

Buy

58.54%

Upside

Reiterated

03/31/26

Analysts Offer Insights on Healthcare Companies: Phreesia (NYSE: PHR), Palisade Bio (NASDAQ: PALI) and Eli Lilly & Co (NYSE: LLY)

Evan Seigerman

BMO Capital

€1,125.05

Buy

37.40%

Upside

Reiterated

03/31/26

Eli Lilly: Strategic Neuroscience Expansion and Diversified Growth Support Continued Buy Rating

David Risinger

Leerink Partners

€1,121.58

Buy

36.98%

Upside

Reiterated

03/30/26

Analysts' Top Healthcare Picks: Centene (CNC), Eli Lilly & Co (LLY)

Emily Field

Barclays

€1,168.32

Buy

42.69%

Upside

Reiterated

03/24/26

Barclays Sticks to Their Buy Rating for Eli Lilly & Co (LLY)

Trung Huynh

RBC Capital

€1,081.78

Buy

32.12%

Upside

Reiterated

03/19/26

Eli Lilly has "viable option' in type 2 diabetes, says RBC CapitalEli Lilly has "viable option' in type 2 diabetes, says RBC Capital

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Eli Lilly & Co

3 Months

xxx

Success Rate

26/35 ratings generated profit

Average Return

+8.32%

reiterated a xxx

rating 9 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 74.29% of your transactions generating a profit, with an average return of +8.32% per trade.

1 Year

Geoff MeachamCiti

Success Rate

40/45 ratings generated profit

Average Return

+37.52%

reiterated a buy rating 10 days ago

Copying Geoff Meacham's trades and holding each position for 1 Year would result in 88.89% of your transactions generating a profit, with an average return of +37.52% per trade.

2 Years

xxx

Success Rate

39/39 ratings generated profit

Average Return

+72.78%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +72.78% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

LLY Analyst Recommendation Trends

Rating

Dec 25

Jan 26

Feb 26

Mar 26

Apr 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

103

105

103

In the current month, LLY has received 91 Buy Ratings, 10 Hold Ratings, and 2 Sell Ratings. LLY average Analyst price target in the past 3 months is 1,069.06.

Each month's total comprises the sum of three months' worth of ratings.

LLY Financial Forecast

LLY Earnings Forecast

Next quarter’s earnings estimate for LLY is €6.11 with a range of €2.67 to €7.00. The previous quarter’s EPS was €6.46. LLY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year LLY has Performed in-line its overall industry.

LLY Sales Forecast

Next quarter’s sales forecast for LLY is €15.05B with a range of €11.70B to €16.30B. The previous quarter’s sales results were €16.54B. LLY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year LLY has Performed in-line its overall industry.

LLY Stock Forecast FAQ

What is DE:LLY’s average 12-month price target, according to analysts?

Based on analyst ratings, Eli Lilly & Co’s 12-month average price target is 1,069.06.

What is DE:LLY’s upside potential, based on the analysts’ average price target?

Eli Lilly & Co has 30.56% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Eli Lilly & Co a Buy, Sell or Hold?

Eli Lilly & Co has a consensus rating of Strong Buy, which is based on 17 buy ratings, 2 hold ratings and 1 sell ratings.

What is Eli Lilly & Co’s share price target?

The average share price target for Eli Lilly & Co is 1,069.06. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €1,286.08 ,and the lowest forecast is €728.78. The average share price target represents 30.56% Increase from the current price of €818.8.

What do analysts say about Eli Lilly & Co?

Eli Lilly & Co’s analyst rating consensus is a Strong Buy. This is based on the ratings of 20 Wall Streets Analysts.

How can I buy shares of Eli Lilly & Co?

To buy shares of DE:LLY, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Eli Lilly & Co (LLY) Stock Forecast & Price Target

LLY Analyst Ratings

LLY Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Eli Lilly & Co

LLY Analyst Recommendation Trends

LLY Financial Forecast

LLY Earnings Forecast

LLY Sales Forecast

LLY Stock Forecast FAQ

Detailed List of Analyst Forecasts